Effects of lowest-dose vs. highest-dose pitavastatin on coronary neointimal hyperplasia at 12-month follow-up in type 2 diabetic patients with non-ST elevation acute coronary syndrome: an optical coherence tomography analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lim, Jung Wook | - |
dc.contributor.author | Jeong, Han Saem | - |
dc.contributor.author | Hong, Soon Jun | - |
dc.contributor.author | Kim, Hyo Jeong | - |
dc.contributor.author | Kim, Young Chan | - |
dc.contributor.author | Kang, Bong Gyun | - |
dc.contributor.author | Jeon, Su Min | - |
dc.contributor.author | Cho, Jae Young | - |
dc.contributor.author | Lee, Seung Hoon | - |
dc.contributor.author | Joo, Hyung Joon | - |
dc.contributor.author | Park, Jae Hyoung | - |
dc.contributor.author | Yu, Cheol Woong | - |
dc.date.accessioned | 2021-09-01T21:45:28Z | - |
dc.date.available | 2021-09-01T21:45:28Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2019-01 | - |
dc.identifier.issn | 0910-8327 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/68389 | - |
dc.description.abstract | Current ACC/AHA guidelines recommend high-dose statin therapy after coronary stenting, especially in diabetic patients; however, pitavastatin 4mg or pitavastatin 1mg are frequently used after coronary stenting in Asia, even in patients with acute coronary syndrome. We compared the effects of highest-dose and lowest-dose pitavastatin therapy on coronary neointimal hyperplasia at 12-month follow-up in diabetic patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) using optical coherence tomography. A total of 72 diabetic patients with NSTE-ACS were randomized to lowest-dose pitavastatin [1mg (n=36)] or highest-dose pitavastatin [4mg (n=36)] after everolimus-eluting stent implantation. The primary endpoint was to compare the normalized neointimal volume at 12-month follow-up. Normalized neointimal volume was significantly lower in the pitavastatin 4mg group (4.002.80 vs. 8.24 +/- 2.83mm(3)/mm, p<0.01) at 12-month follow-up. There was also significant difference in neointimal area between the pitavastatin 4mg group and pitavastatin 1mg group (0.41 +/- 0.28 vs. 0.74 +/- 0.23mm(2), p<0.01). Improvement of brachial artery flow-mediated dilation (baFMD) was significantly higher in the pitavastatin 4mg group than in pitavastatin 1mg group (0.15 +/- 0.15 vs. -0.03 +/- 0.19mm, p<0.001). In addition, the improvement of adiponectin levels was significantly greater in the pitavastatin 4mg group than in the pitavastatin 1mg group (2.97 +/- 3.98 vs. 0.59 +/- 2.80g/mL, p<0.05). Pitavastatin 4mg significantly improved inflammatory cytokines and lipid profiles compared to pitavastatin 1mg during the 12-month follow-up, contributing to the reduction of neointimal hyperplasia and to the improvement of baFMD in diabetic patients with NSTE-ACS requiring coronary stenting. Thus, the administration of pitavastatin 4mg can be safely and effectively used in high-risk patients requiring coronary stenting. Trial registration NCT02545231 (Clinical Trial registration information: https://clinicaltrials.gov/ct2/show/NCT02545231) | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | MODERATE-INTENSITY STATINS | - |
dc.subject | ELUTING STENT IMPLANTATION | - |
dc.subject | INTRAVASCULAR ULTRASOUND | - |
dc.subject | EFFICACY | - |
dc.subject | RESTENOSIS | - |
dc.subject | METAANALYSIS | - |
dc.subject | CHOLESTEROL | - |
dc.subject | REGRESSION | - |
dc.subject | OUTCOMES | - |
dc.subject | SAFETY | - |
dc.title | Effects of lowest-dose vs. highest-dose pitavastatin on coronary neointimal hyperplasia at 12-month follow-up in type 2 diabetic patients with non-ST elevation acute coronary syndrome: an optical coherence tomography analysis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Hong, Soon Jun | - |
dc.contributor.affiliatedAuthor | Joo, Hyung Joon | - |
dc.contributor.affiliatedAuthor | Yu, Cheol Woong | - |
dc.identifier.doi | 10.1007/s00380-018-1227-0 | - |
dc.identifier.scopusid | 2-s2.0-85050659051 | - |
dc.identifier.wosid | 000456727100008 | - |
dc.identifier.bibliographicCitation | HEART AND VESSELS, v.34, no.1, pp.62 - 73 | - |
dc.relation.isPartOf | HEART AND VESSELS | - |
dc.citation.title | HEART AND VESSELS | - |
dc.citation.volume | 34 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 62 | - |
dc.citation.endPage | 73 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.relation.journalWebOfScienceCategory | Peripheral Vascular Disease | - |
dc.subject.keywordPlus | MODERATE-INTENSITY STATINS | - |
dc.subject.keywordPlus | ELUTING STENT IMPLANTATION | - |
dc.subject.keywordPlus | INTRAVASCULAR ULTRASOUND | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | RESTENOSIS | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | CHOLESTEROL | - |
dc.subject.keywordPlus | REGRESSION | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordAuthor | Acute coronary syndrome | - |
dc.subject.keywordAuthor | Diabetic patients | - |
dc.subject.keywordAuthor | Pitavastatin | - |
dc.subject.keywordAuthor | Optical coherence tomography | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.